Global Nontuberculous Mycobacterial Infection Market to Reach $19.57 Billion by 2029, Growing at 6.7% CAGR

What industry-specific factors are fueling the growth of the nontuberculous mycobacterial infection market?
The surge in occurrences of chronic obstructive pulmonary disease (COPD) is anticipated to boost the nontuberculous mycobacterial infection market's expansion. COPD is a chronic breathing disorder distinguished by consistent and frequently deteriorating lung airflow restriction. Nontuberculous mycobacterial (NTM) infections are noticeable in COPD patients because they lead to a severe decrease in forced expiratory volume in one second (FEV1) and a higher rate of exacerbation. COPD can impair the immune system and harm the lung tissue, rendering it more vulnerable to NTM bacteria. For example, The Scottish Public Health Observatory (ScotPHO) reported in March 2023 that the rates of COPD started to increase from 2021 to 2022. Male rates rose from 83.2 to 97.6 per 100,000 persons, while female rates increased from 72.6 to 97.3. Consequently, the growing occurrence of COPD is fueling the nontuberculous mycobacterial infection market's growth. The Nontuberculous Mycobacterial Infection Market's growth is being driven by the increasing rate of infectious diseases. These illnesses are caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, which can be transmitted between individuals, causing a variety of symptoms and health issues. The escalating occurrence of infectious diseases, including conditions that can lead to NTM infections, could potentially speed up the NTM infection market's growth by raising public consciousness about these infections. This leads to more routine diagnostic tests and early detection, more research and development for NTM treatments, and increased demand for therapies that target NTM pathogens due to an elevated focus on infectious diseases in healthcare. For example, in November 2024, the United Nations International Children's Emergency Fund (UNICEF) reported that pneumonia was the leading infectious disease, causing over 700,000 children's deaths annually or about 2,000 children per day. Therefore, the escalating prevalence of infectious diseases is propelling the nontuberculous mycobacterial infection market's growth.

Get Your Nontuberculous Mycobacterial Infection Market Report Here:
https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

What Is the projected market size and growth rate for the nontuberculous mycobacterial infection market?
In recent times, there has been substantial growth in the market size for nontuberculous mycobacterial infection. The market, which stood at $14.25 billion in 2024, is projected to reach $15.11 billion in 2025, growing at a compound annual growth rate (CAGR) of 6.0%. This increase observed in the historic period is mainly due to enhanced diagnostic techniques, an aging populace, raised awareness of cystic fibrosis, and the use of immunosuppressive drugs.

Strong expansion is projected in the upcoming years for the nontuberculous mycobacterial infection market, with the expectation to soar to $19.57 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.7%. Driving forces behind this anticipated growth during the forecast period include the development of antimicrobial drugs, enhanced awareness of ntm, advances in the field of genetic research, telehealth, and remote monitoring. Key trends that are likely to shape the forecast period encompass personalized treatments, regulatory emphasis, combined therapies, and digital health instruments.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp

What new trends are reshaping the nontuberculous mycobacterial infection market and its opportunities?
Major corporations that are active in the nontuberculous mycobacterial infection market employ updated treatment approval strategies such as fast track designation for medication approval in order to maintain their market prominence. The Fast Track designation by the FDA is a method aimed at speeding up the review and development of medications for severe conditions that have unfulfilled medical needs. For example, in July 2022, the Food and Drug Administration, an American federal entity, awarded NUZYRA Fast Track Designation for the treatment of nontuberculous mycobacterial (NTM) lung disease resulting from Mycobacterium avium complex (MAC). NUZYRA (omadacycline) is an innovative broad-range antibiotic created to combat severe bacterial infections, inclusive of those induced by resistant strains. This designation enables accelerated development and review for the NUZYRA antibiotic in order to meet substantial unmet medical needs.

What major market segments define the scope and growth of the nontuberculous mycobacterial infection market?
The nontuberculous mycobacterial infection market covered in this report is segmented -

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Macrolides: Azithromycin, Clarithromycin
2) By Rifampin: Rifampin, Rifabutin
3) By Aminoglycoside: Amikacin, Streptomycin
4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13020

Which region dominates the nontuberculous mycobacterial infection market?
North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Which key market leaders are driving the nontuberculous mycobacterial infection industry growth?
Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp

What Is Covered In The Nontuberculous Mycobacterial Infection Global Market Report?

•Market Size Forecast: Examine the nontuberculous mycobacterial infection market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the nontuberculous mycobacterial infection market for a structured understanding.
•Key Players Overview: Analyze major players in the nontuberculous mycobacterial infection market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the nontuberculous mycobacterial infection market.
•Segment Contributions: Evaluate how different segments drive overall growth in the nontuberculous mycobacterial infection market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the nontuberculous mycobacterial infection market.
•Industry Challenges: Identify potential risks and obstacles affecting the nontuberculous mycobacterial infection market.
•Competitive Landscape: Review strategic developments in the nontuberculous mycobacterial infection market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.